Composition for inhibiting the expression of FcεRI and method for inhibiting the expression of FcεRI
By using the cells and cultures of *Pediococcus* lactic acid bacteria, a composition capable of inhibiting FcεRI expression in pDC cells has been successfully developed, solving the problem of inhibiting FcεRI expression in existing technologies. This achieves antiviral, anti-infective, and anti-allergic effects, and the composition is safe for use in a variety of products.
Patent Information
- Application Number
- CN201980052277.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-08-09
- Filing Date
- 2019-08-08
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2039-08-08
AI Technical Summary
There is a lack of effective substances in the current technology that can inhibit the expression of FcεRI on the surface of human pDC cells, leading to an increase in allergic reactions and viral infections, and existing screening methods are difficult to obtain effective components.
Using the cells, cell components, and cultures of *Pediococcus* lactic acid bacteria as active ingredients, a co-culture experiment was conducted to screen out a composition that inhibited FcεRI expression in pDC cells and promoted the production of IFN-α.
It effectively inhibits FcεRI in pDC cells and has antiviral, anti-infective, anti-allergic, anti-hay fever and anti-asthma effects. The composition is safe for use in food, medicine and cosmetics.
Smart Images

Figure CN112543641B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a composition for inhibiting the expression of FcεRI and a method for inhibiting the expression of FcεRI. Background Art
[0002] In recent years, the number of patients suffering from allergic diseases classified as type I allergies, such as bronchial asthma, allergic rhinitis, hay fever, atopic dermatitis, psychological allergic reaction, urticaria, and food allergy, has been increasing.
[0003] In type I allergy, first, as allergens (antigens) such as pollen and mold enter the living body, IgE corresponding to the allergen is produced by B cells. The produced IgE binds to the high-affinity IgE receptor (FcεRI) expressed on the surface of mast cells (fat cells) and basophils (sensitization).
[0004] In this sensitized state, the allergen that invades the body again binds to the two or more IgEs that bind to each FcεRI, and the two or more FcεRIs are cross-linked via IgE (cross-linking reaction). At this time, mast cells and basophils are activated and degranulate, releasing chemical mediators such as histamine and serotonin. As a result, allergic symptoms appear due to vascular dilation and hyperpermeability, migration of white blood cells, etc.
[0005] On the other hand, among dendritic cells, plasmacytoid dendritic cells (pDC) have FcεRI on the cell surface. Due to the invasion of allergens into the body, cross-linking reactions may occur in pDC. Unlike myeloid dendritic cells (mDC) with a dendritic morphology, pDC exists in peripheral blood and exhibits characteristics similar to plasma cells. When stimulated by absorbing foreign substances such as viruses, pDC differentiates into dendritic cell-like cells.
[0006] When pDCs respond to viruses as foreign substances, they produce a large amount of type I IFN such as interferon-α (IFN-α). Due to the antiviral effect of type I IFN, the proliferation or replication of viruses can be inhibited, and the natural immunity can be activated.
[0007] However, on the pDC cell surface, when IgE antibodies react with each other via allergens, the expression of TLR (Toll like receptor) and interferon regulatory factor (IRF), a cell surface and cell membrane-penetrating pattern recognition receptor used by pDC to sense foreign substances, is suppressed. As a result, the production of IFN-α by pDC is suppressed (refer to Non-Patent Document 1 described later, the entire contents of which are cited as disclosed herein).
[0008] Therefore, the antiviral effect of pDC is expected, and in order to inhibit the cross-linking reaction in pDC, it is conceivable to inhibit the expression of FcεRI, which shows a high affinity for IgE antibodies. For example, in the patent documents 1 to 3 described below (the entire contents of these documents are hereby cited as public), a DNA that regulates the transcription of the FcεRI gene and a method for screening a substance that inhibits the expression of the FcεRI gene using the DNA as an index are described.
[0009] Prior art literature
[0010] Patent Literature
[0011] Patent Document 1: Japanese Patent No. 5131688
[0012] Patent Document 2: International Publication No. 2004 / 108929
[0013] Patent Document 3: International Publication No. 1999 / 46393
[0014] Non-patent literature
[0015] Non-patent document 1: Michelle Ann Gill, J Allergy Clin Immunol, April 2012, Vol. 129, Number 4, pp. 889-901 Summary of the invention
[0016] Problems to be solved by the invention
[0017] According to Patent Documents 1 to 3, there is a possibility that a substance that inhibits the expression of the FcεRI gene can be screened. However, Patent Documents 1 to 3 do not describe obtaining such a substance through screening. In fact, it is difficult to obtain a substance that inhibits the expression of the FcεRI gene using the screening methods described in Patent Documents 1 to 3.
[0018] In addition, little is known about substances that can be used in humans, have experience in consumption or ingestion, and have an inhibitory effect on the expression of FcεRI on DCs.
[0019] Therefore, the problem to be solved by the present invention is to provide a composition having experience of being eaten or ingested by humans and containing, as an active ingredient, a substance that exhibits an effect of inhibiting the expression of FcεRI present on the surface of pDC cells.
[0020] Means for solving problems
[0021] As a result of intensive research conducted by the present inventors to solve the above-mentioned problems, they discovered that Pediococcus acidilactici ( Pediococcus acidilactici ) and Pediococcus pentosaceus (P. pentosaceus ) has an inhibitory effect on the expression of FcεRI of pDC. On the other hand, the existence of lactic acid bacteria that promote the production of IFN-α by pDC and do not inhibit the expression of FcεRI was found. The fact that there is no correlation between the inhibitory effect on the expression of FcεRI of pDC and the effect of promoting the production of IFN-α is a very surprising fact discovered for the first time by the present inventors.
[0022] Based on this fact, the present inventors have successfully created a composition containing, as an active ingredient, bacterial cells, bacterial components, cultured products, and processed products thereof of Pediococcus lactic acid bacteria, and having an inhibitory effect on the expression of FcεRI of pDC. The present invention was ultimately completed based on these findings and successful examples.
[0023] Therefore, according to one embodiment of the present invention, a composition, method and application in the following manner are provided.
[0024] [1] A composition for activating plasmacytoid dendritic cells, comprising at least one active ingredient selected from the group consisting of bacterial cells, bacterial cell components, cultures, and processed products thereof of Pediococcus lactic acid bacteria, and having an inhibitory effect on the expression of FcεRI in plasmacytoid dendritic cells.
[0025] [2] The composition according to [1], which has an effect of promoting the production of interferon-α by plasmacytoid dendritic cells.
[0026] [3] The composition according to [1] or [2], wherein the Pediococcus lactic acid bacteria is selected from Pediococcus acidilactici ( Pediococcus acidilactici ) and Pediococcus pentosaceus ( P. pentosaceus ) of at least one lactic acid bacterium of the genus Pediococcus.
[0027] [4] The composition according to any one of [1] to [3], wherein the composition has and uses an amount of Lactobacillus pentosus ( Lactobacillus pentosus )K133 strain, and had a higher inhibitory effect on the expression of FcεRI in plasmacytoid dendritic cells than that in the control group.
[0028] [5] The composition according to any one of [1] to [4], which is at least one anti-disease composition selected from the group consisting of an antiviral composition, an anti-infective composition, an anti-allergic composition, an anti-hay fever composition, and an anti-asthma composition.
[0029] [6] A composition for a food or drink comprising the composition according to any one of [1] to [5].
[0030] [7] A method for screening lactic acid bacteria for activating plasmacytoid dendritic cells, comprising:
[0031] The steps of culturing a test solution containing at least one component selected from the group consisting of bacterial cells, bacterial components, and culture products of lactic acid bacteria and processed products thereof, and plasmacytoid dendritic cells, and culturing a control solution containing no such component and containing plasmacytoid dendritic cells;
[0032] A step of measuring the expression level of FcεRI in the plasmacytoid dendritic cells in the test solution and the control solution after culture; and
[0033] A step of determining that the component has an effective component for activating plasmacytoid dendritic cells when the measured expression level of FcεRI by plasmacytoid dendritic cells in the test solution is lower than the expression level of FcεRI by plasmacytoid dendritic cells in the control solution.
[0034] [8] A method for screening lactic acid bacteria for activating plasmacytoid dendritic cells, comprising:
[0035] The steps of culturing a test solution containing at least one component selected from the group consisting of bacterial cells, bacterial components, and culture products of lactic acid bacteria and processed products thereof, and plasmacytoid dendritic cells, and culturing a control solution containing no such component and containing plasmacytoid dendritic cells;
[0036] A step of measuring the amount of interferon-α produced by the plasmacytoid dendritic cells and the amount of FcεRI expressed by the plasmacytoid dendritic cells in the test solution and the control solution after the culture; and
[0037] A process for determining that the component is an effective component for activating plasmacytoid dendritic cells when the amount of interferon-α produced in the test solution is greater than the amount of interferon-α produced in the control solution and the amount of FcεRI expressed in the test solution is less than the amount of FcεRI expressed in the control solution.
[0038] [9] A method for inhibiting the expression of FcεRI by plasmacytoid dendritic cells using at least one active ingredient selected from the group consisting of bacterial cells, bacterial components, cultures, and processed products thereof of lactic acid bacteria of the genus Pediococcus.
[0039]
[10] Use of at least one active ingredient selected from the group consisting of bacterial cells, bacterial cell components, and cultures of lactic acid bacteria of the genus Pediococcus and processed products thereof for producing a composition for inhibiting the expression of FcεRI by plasmacytoid dendritic cells.
[0040]
[11] Use of at least one active ingredient selected from the group consisting of bacterial cells, bacterial cell components, cultures, and processed products thereof of lactic acid bacteria of the genus Pediococcus for inhibiting the expression of FcεRI by plasmacytoid dendritic cells.
[0041] Effects of the Invention
[0042] The composition of one embodiment of the present invention has an effect of inhibiting the expression of FcεRI of pDC, and further, in association with this effect, is expected to have antiviral effects, anti-infective effects, anti-allergic effects, anti-hay fever effects, anti-asthma effects, and the like.
[0043] The active ingredient used in the composition of one embodiment of the present invention has been used as an additive for food and drink. Therefore, the composition of one embodiment of the present invention is highly safe and is useful as food and drink, pharmaceuticals, cosmeceuticals, cosmetics, etc. with antiviral effects, anti-infective effects, anti-allergic effects, anti-hay fever effects, and anti-asthma effects, and is expected to be provided in an oral or parenteral form. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] Figure 1 It is a graph showing the results of measuring the relative expression levels of FcεRI of pDC in Lactobacillus pentosaceus K133 strain ("K133"), Pediococcus pentosaceus NRIC99 strain ("NRIC99"), and Pediococcus acidilactici K226 strain, K531 strain, JCM8797 strain, and K15 strain ("K226", "K531", "JCM8797", and "K15") as described in the Examples.
[0045] Figure 2 This is a graph showing the results of measuring the amount (relative amount) of FcεRI mRNA produced by pDC cultured with TLR7 ligand, TLR8 ligand, TLR9 ligand and Pediococcus acidilactici K15 strain ("K15") as described in the Examples. In addition, "Med" shows the control (measurement results when lactic acid bacteria were not added). DETAILED DESCRIPTION
[0046] The present invention will be described in detail below, but the technical scope of the present invention is not limited to the matters of this project, and the present invention can take various forms as long as the object can be achieved.
[0047] The composition according to one embodiment of the present invention contains at least one active ingredient (hereinafter, sometimes simply referred to as "active ingredient") selected from the group consisting of bacterial cells, bacterial cell components, cultures, and processed products thereof of lactic acid bacteria of the genus Pediococcus.
[0048] The composition of one embodiment of the present invention, due to the effective ingredients contained, can have an inhibitory effect on the expression of FcεRI of plasmacytoid dendritic cells, or an inhibitory effect on the expression of FcεRI of plasmacytoid dendritic cells and an effect of promoting the production of interferon-α of plasmacytoid dendritic cells. In this specification, these effects are sometimes collectively referred to as "effective effects". The composition of one embodiment of the present invention, due to its effective effects, can representatively take the form of a composition for activating plasmacytoid dendritic cells. Another embodiment of the present invention is a method of using an effective ingredient to inhibit the expression of FcεRI of plasmacytoid dendritic cells.
[0049] Unless otherwise specified, each term in this specification is used with the meaning commonly used by those skilled in the art and should not be interpreted as having an unreasonable limited meaning.
[0050] For example, the term "composition" is not particularly limited in its commonly used meaning, and it may be, for example, a combination of two or more substances. Specifically, it may include a combination of active ingredients and other substances, a combination of two or more active ingredients, etc. More specifically, it may include solid compositions and liquid compositions composed of one or more active ingredients and one or more solid carriers or solvents.
[0051] The term "expression inhibitory effect" on plasmacytoid dendritic cells refers to at least one effect selected from the group consisting of suppressing the expression level of a gene, reducing the translation level of a gene product (protein), and activating plasmacytoid dendritic cells to inhibit the production of a gene product.
[0052] The term "production-promoting effect" on plasmacytoid dendritic cells refers to at least one effect selected from the group consisting of promoting the expression level of a gene, increasing the translation amount of a gene product, and activating plasmacytoid dendritic cells to produce a gene product.
[0053] The term "plasmacytoid dendritic cells activated" means that the plasmacytoid dendritic cells are put into a state of exhibiting effective action by the effective ingredient.
[0054] The term "and / or" means any one of the listed multiple associated items, or any combination of two or more, or all combinations.
[0055] FcεRI (high affinity IgE receptor) is not particularly limited as a commonly known meaning, and can be, for example, a receptor with high affinity for the Fc portion of IgE on the surface of plasmacytoid dendritic cells and obese cells. FcεRI has three subunits, namely, an α chain, a β chain, and a γ chain. It is known that mast cells and basophils have an αβγ2 tetramer structure and an αγ2 trimer structure, while dendritic cells such as plasmacytoid dendritic cells, monocytes, eosinophils, etc. have an αγ2 trimer structure and are expressed on the cell surface.
[0056] When an antigen binds to two or more IgEs that bind to the α chain of FcεRI (FcεRI-IgE), FcεRI becomes cross-linked by the antigen. This cross-linking causes intracellular signaling via the γ chain and the β chain, activating plasmacytoid dendritic cells and / or obese cells.
[0057] Interferon (IFN)-α is a type I interferon that has an antiviral effect that inhibits viral proliferation and / or replication. In addition, IFN-α has the following effects: inhibiting the proliferation of cells infected with viruses, activating cells related to natural immunity such as macrophages and natural killer cells (NK cells), anti-tumor effects, and inhibiting the development of intracellular parasites other than viruses. IFN-α is used clinically as a therapeutic drug for viral hepatitis.
[0058] Plasmacytoid dendritic cells (pDCs) are cells that exist in peripheral blood and show characteristics similar to plasma cells. When stimulated by absorbing foreign substances, they differentiate into dendritic cell-like cells. The active ingredient acts on pDCs to bring about an effective effect.
[0059] The method for evaluating the inhibitory effect on FcεRI expression is not particularly limited, and for example, the effect can be evaluated by measuring the expression level of FcεRI expressed by pDCs as described in the Examples below.
[0060] A specific example of the evaluation method of the inhibitory effect of FcεRI expression includes: co-culturing pDCs derived from each subject and a composition of one embodiment of the present invention, and then using the cells or culture supernatant recovered after the culture as the test sample, using a commercially available labeled anti-FcεRI antibody to label FcεRI on the cell surface, and then measuring the labeling intensity by flow cytometry, etc.; and / or using a commercially available kit to measure the amount of FcεRI mRNA in the cells or culture supernatant, and a method for measuring the expression amount of FcεRI in pDCs derived from each subject, etc., but it is not limited thereto. The conditions for co-culture are not particularly limited, and can include, for example, conditions that do not inhibit the expression of FcεRI and do not kill pDCs, etc. Preferably, culture conditions such as a culture medium, temperature, CO2 concentration, pH, etc. suitable for the maintenance or proliferation of pDCs are used.
[0061] The number of subjects in the method for evaluating the inhibitory effect on the expression of FcεRI is preferably 2 or more, and more preferably 3 or more, in consideration of the differences between individuals. The inhibitory effect on the expression of FcεRI is evaluated by taking the average of the relative values obtained based on the expression level of FcεRI of pDC derived from each subject with respect to the control (a system in which the composition of one embodiment of the present invention is not used) as the reference. For example, the expression level of FcεRI of pDC derived from subject A, subject B, ... subject X, i.e., D, is measured. A , D B , ...D X , then according to D A , D B , ...D X The relative value R is calculated based on the control. A , R B , ……R X , then according to R A , R B , ……R X Find the average relative value AR AB……X to make an evaluation.
[0062] The degree of the inhibitory effect on the expression of FcεRI is not particularly limited, and for example, the degree to which the expression level of FcεRI on pDC is evaluated to be reduced compared to the case where the composition of one embodiment of the present invention is not used (control). However, preferably, the degree of the inhibitory effect on the expression of FcεRI is such that any of the expression levels of FcεRI on pDC derived from each subject is evaluated to be smaller than that of the control (in the above example, 1>R A , 1>R B , ... 1 > R X ) to a certain extent.
[0063] As described in the Examples below, due to the FcεRI expression inhibition effect of Pediococcus lactic acid bacteria, there are more Lactobacillus pentosus ) K133 strain has a greater effect, so it is more preferred that the FcεRI expression inhibition effect in the composition of one embodiment of the present invention is compared with the use of an amount of Lactobacillus pentosus ( Lactobacillus pentosus )K133 strain, the expression level of FcεRI of pDC was evaluated to be smaller. This more preferred embodiment, with respect to the above example, is the average relative value AR obtained by using the composition of one embodiment of the present invention. AB……X Compared with using an amount of Lactobacillus pentosus ( Lactobacillus pentosus )K133 strain and the average relative value AR AB……X To a small extent.
[0064] When the Pediococcus lactic acid bacterium is Pediococcus acidilactici, the extent of the inhibitory effect on FcεRI expression is preferably such that the expression level of FcεRI on pDC is evaluated to be smaller than when an equal amount of Pediococcus pentosaceus NRIC99 strain is used as the active ingredient.
[0065] The degree of inhibition of FcεRI expression was, for example, determined by co-culturing 1×10 7 Pediococcus lactic acid bacteria and 2.5×10 4 The average relative value of the expression level of FcεRI of pDCs and cells collected 24 hours later is about 0.93 or less, preferably about 0.90 or less, more preferably about 0.85 or less, further preferably about 0.83 or less, and further preferably about 0.81 or less. In addition, although the lower limit is not particularly limited, it is typically 0.10 or more.
[0066] The method for evaluating the effect of promoting IFN-α production is not particularly limited, and for example, it can be evaluated by measuring the amount of IFN-α produced by pDCs and / or the expression level of IFN-α gene expressed by pDCs as described in the Examples below.
[0067] A specific example of a method for evaluating the effect of promoting the production of IFN-α includes: co-culturing pDC and a composition of an embodiment of the present invention, and then using the culture supernatant recovered after the culture as a sample solution, and using a commercially available IFN-α assay kit to measure the IFN-α concentration, etc., but is not limited thereto. The conditions for co-culture are not particularly limited, and for example, conditions in which IFN-α is not inactivated and pDC does not die can be cited. Preferably, culture conditions such as a culture medium, temperature, CO2 concentration, pH, etc. suitable for the maintenance or proliferation of pDC are used.
[0068] The degree of the effect of promoting the production of IFN-α is not particularly limited, but is preferably the degree to which the amount of IFN-α produced by pDC increases compared to when the composition of one embodiment of the present invention is not used. When the lactic acid bacteria of the genus Pediococcus are Pediococcus acidilactici, the degree of the effect of promoting the production of IFN-α is the degree to which the amount of IFN-α produced by pDC increases compared to when the Pediococcus pentosaceus NRIC99 strain is used in an amount equal to the active ingredient.
[0069] In addition, the degree of effective action is preferably, for example, 1×10 7 Pediococcus lactic acid bacteria and 2.5×10 4 The IFN-α concentration in the supernatant collected 24 hours after the pDC was isolated (average value among subjects) was about 10 pg / ml or more, more preferably about 100 pg / ml or more. Although the upper limit is not particularly limited, it is typically 10000 pg / ml or less.
[0070] The composition of one embodiment of the present invention has effective effects and is expected to have antiviral effects, anti-infective effects, anti-allergic effects, anti-hay fever effects and anti-asthma effects, so the embodiments of the composition can be antiviral compositions, anti-infective compositions, anti-allergic compositions, anti-hay fever compositions and anti-asthma compositions.
[0071] The antiviral effect, anti-infective effect, anti-allergic effect, anti-hay fever effect and anti-asthma effect of the composition of one embodiment of the present invention refer to, for example, in the case of the antiviral effect, the improvement, alleviation or treatment of the symptoms of a viral disease in the present or future of the individual who takes the composition of one embodiment of the present invention, or the inhibition, delay or prevention of the state of suffering from a viral disease. In addition, for the anti-asthma effect, it is known that the anti-IgE antibody, i.e., omalizumab, can improve asthma symptoms, and part of the mechanism is believed to be due to the inhibitory effect of FcεRI expression. (For example, refer to non-patent document 1, William W.Busse, et al., N Engl J Med, March 2011, Vol.17, Number 364, pp.1005-1015, Calman Prussin, et al., J Allergy Clin Immunol, December 2003, Vol.112, Number 6, pp1147-1154; all records of these documents are cited as public).
[0072] In non-patent document 1, it is recorded that due to the presence of allergens, FcεRI in pDC undergoes a cross-linking reaction, and the production of IFN-α decreases. In addition, in the document by Michelle et al. (Michelle A. Gill et al., J Immunol. 2010 June 1; 184 (11): 5999-6006; all records of the document are cited as public), it is recorded that: compared with healthy people, asthma patients have a high expression of FcεRI in pDC; compared with healthy people with influenza, asthma patients with influenza have a low production of IFN-α in pDC. Taking these records into consideration, it is believed that the composition of one embodiment of the present invention has a high antiviral effect and anti-infective effect in asthma patients.
[0073] The composition according to one embodiment of the present invention contains as an active ingredient at least one selected from the group consisting of bacterial cells, bacterial cell components, and cultures of lactic acid bacteria of the genus Pediococcus, and processed products thereof.
[0074] The lactic acid bacteria of the genus Pediococcus are not particularly limited as long as they are cocci that produce Gram-positive lactic acid as generally known, that is, lactic acid bacteria belonging to the genus Pediococcus , and examples thereof include lactic acid bacteria of the genus Pediococcus that have been used as food.
[0075] The method for obtaining Pediococcus lactic acid bacteria is not particularly limited. For example, Pediococcus lactic acid bacteria can be isolated as an isolated strain from lactic acid bacteria-containing substances such as pickles, sake lees, dairy products, soy sauce and moromi, or can be a strain distributed from the American Type Culture Collection (ATCC), Tokyo University of Agriculture and Technology (NRIC), RIKEN (JCM), National Biotechnology Center (NBRC), and National Institute of Technology for Evaluation and Research, ...
[0076] Specific examples of lactic acid bacteria of the genus Pediococcus include: Pediococcus acidilactici ( Pediococcus acidilactici ), Pediococcus pentosaceus ( Pediococcus pentosaceus )、Pediococcus cerevisiae( Pediococcus cellicola ), Pediococcus krusei ( Pediococcus clausenii ), harmful Pediococcus ( Pediococcus damnosus ), ethanol-resistant Pediococcus ( Pediococcus ethanolidurans )、Pediococcus accidentalis( Pediococcus inopinatus ), Pediococcus microti ( Pediococcus parvulus ), Pediococcus stinjuni ( Pediococcus stilesii ) etc., but are not limited thereto. As the Pediococcus lactic acid bacteria, any one of them may be used alone, or two or more thereof may be used in combination.
[0077] Non-limiting examples of Pediococcus acidilactici and Pediococcus pentosaceus include Pediococcus acidilactici K15 strain, Pediococcus acidilactici K226 strain, Pediococcus acidilactici K531 strain, Pediococcus acidilactici NRICO 124 strain, Pediococcus acidilactici JCM8797 strain, Pediococcus pentosaceus OS strain (NITE P-354), Pediococcus pentosaceus NRIC1915 strain, Pediococcus pentosaceus NRIC99 strain, Pediococcus pentosaceus NRIC122 strain, Pediococcus pentosaceus JCM2024 strain, Pediococcus pentosaceus ATCC33314 strain, and the like.
[0078] Among the lactic acid bacteria of the genus Pediococcus, Pediococcus acidilactici and Pediococcus pentosaceus are preferred in terms of their large effective effects and rich consumption experience; Pediococcus acidilactici is more preferred in terms of their even greater effective effects; Pediococcus acidilactici K15, Pediococcus acidilactici K226, Pediococcus acidilactici K531 and Pediococcus acidilactici JCM8797 are further preferred.
[0079] Hereinafter, a composition according to one embodiment of the present invention will be described in detail assuming that Pediococcus acidilactici is used as a Pediococcus lactic acid bacterium. However, when a Pediococcus lactic acid bacterium other than Pediococcus acidilactici is used, the description of "Pediococcus acidilactici" below may be replaced with another Pediococcus lactic acid bacterium such as "Pediococcus pentosaceus".
[0080] The method of isolating Pediococcus acidilactici is not particularly limited, and examples thereof include a method of appropriately diluting an extract of a lactic acid bacteria-containing substance according to a conventional method, using a known lactic acid bacteria culture medium such as an MRS medium and an M17 medium, and culturing the extract at about 30° C. to 40° C. For example, Pediococcus acidilactici K15, K226, and K531 are lactic acid strains isolated from rice bran, pickled vegetables, and grapes for wine, respectively, as lactic acid bacteria-containing substances, and the optimal temperature for each of them is about 37° C. to 42° C.
[0081] According to the investigation of the present inventors, Pediococcus acidilactici can contain high concentrations of double-stranded RNA by culturing under stress conditions. Examples of Pediococcus acidilactici with high double-stranded RNA content include: 10 CFU of Pediococcus acidilactici containing more than 1500ng of double-stranded RNA and 1×10 10 The ratio of double-stranded RNA to the total amount of nucleic acid in cfu bacteria is 3.5% or more in Pediococcus acidilactici, etc. In addition, although the upper limits are not particularly limited, they are typically 200,000 ng or less and 99% or less, respectively.
[0082] Stress conditions refer to conditions other than the conditions for culturing lactic acid bacteria in general, such as high salt concentration, high temperature, low temperature, oligotrophy, eutrophy, low pH, high pH, aeration, and combinations thereof, and preferably conditions in which the doubling time of lactic acid bacteria is longer than when cultured under appropriate conditions.
[0083] Specifically, the culture under stress conditions caused by salt includes, for example, culture using a medium containing 0.5% (w / v) to 30% (w / v), preferably 5% (w / v) to 15% (w / v) of salt, etc. In a medium with a salt concentration of 0.5% (w / v) or less or 30% (w / v) or more, the growth of Pediococcus acidilactici is extremely slow, which is not preferred.
[0084] Cultivation under stress conditions caused by high or low temperature can be performed at an optimal temperature ±1°C to 30°C suitable for the growth of Pediococcus acidilactici, preferably at an optimal temperature ±5°C to 20°C. Specifically, if the optimal temperature of Pediococcus acidilactici is 40°C, culturing can be performed at 10°C to 39°C or 41°C to 60°C.
[0085] Cultivation under stress conditions caused by ventilation can be exemplified by culturing under conditions such as supplying air and stirring to increase the dissolved oxygen concentration. In this case, oxygen can be used instead of air, and oscillation other than stirring can be used as long as the dissolved oxygen concentration can be increased. In addition, the stirring speed can be appropriately set according to the size of the culture tank, etc.
[0086] The air supply (ventilation rate) is not particularly limited, and is, for example, about 0.01VVM to 10VVM per unit volume, preferably about 0.1VVM to 1VVM. When the ventilation rate is less than 0.01VVM, the dissolved oxygen concentration may not be increased, and when the ventilation rate is greater than 10VVM, the lactic acid bacteria may be physically damaged due to a large number of bubbles, so these situations are not preferred.
[0087] As other conditions for culturing Pediococcus acidilactici, conditions suitable for the proliferation of Pediococcus acidilactici may be used. For example, as a culture medium used, a culture medium commonly used in the culture of Pediococcus acidilactici may be used. Examples of such culture medium include, but are not limited to, MRS culture medium and M17 culture medium. In addition, the culture time is not particularly limited as long as the proliferation of Pediococcus acidilactici is observed and a sufficient bacterial cell density can be obtained.
[0088] By culturing under stress conditions, Pediococcus acidilactici can produce more bacterial components such as double-stranded RNA, compared to the case of culturing without stress conditions.
[0089] The Pediococcus acidilactici may be cultured under stress conditions or cultured under normal conditions. The Pediococcus acidilactici may be, for example, a combination of one or more species of Pediococcus acidilactici cultured under stress conditions and one or more species of Pediococcus acidilactici cultured under normal conditions.
[0090] The active ingredient in the composition of one embodiment of the present invention may be Pediococcus acidilactici itself, that is, in addition to the cells of Pediococcus acidilactici, it may also be a cell component of Pediococcus acidilactici, a culture of Pediococcus acidilactici, or a processed product of any of the cells, cell components and culture of Pediococcus acidilactici.
[0091] Examples of the bacterial cells of Pediococcus acidilactici include those obtained by removing the culture medium from a culture of Pediococcus acidilactici using a generally known solid-liquid separation means such as centrifugation.
[0092] Examples of the bacterial components of Pediococcus acidilactici include purified or non-purified components present in the bacterial body or secreted outside the bacterial body of Pediococcus acidilactici, and specifically include single-stranded RNA, double-stranded RNA, single-stranded DNA, and double-stranded DNA.
[0093] Examples of the culture material of Pediococcus acidilactici include a culture solution itself obtained by culturing Pediococcus acidilactici.
[0094] Examples of processed products of Pediococcus acidilactici cells, cell components and cultures include those obtained by subjecting Pediococcus acidilactici cells, cell components and cultures to a generally known method for treating lactic acid bacteria cells, cell components and cultures, such as sterilization treatment and drying treatment.
[0095] The culture of Pediococcus acidilactici is sterilized, the culture medium is removed from the culture medium using a generally known solid-liquid separation means such as an ultrafiltration membrane and a centrifugal concentrator to recover the cells, and then the cells are washed with a washing liquid such as water and saline to obtain the cells of Pediococcus acidilactici. The cells thus obtained can be kept as they are, or a mixture with a food raw material of a sugar such as dextrin, and a dry powder obtained by drying can be used as an effective ingredient. The method of drying treatment is not particularly limited, and examples thereof include natural drying, air drying, spray drying, freeze drying, and the like. From the perspective of storage and ease of handling in manufacturing, the effective ingredient of the composition containing one embodiment of the present invention is preferably a dry powder of Pediococcus acidilactici.
[0096] The active ingredient is not particularly limited as long as it is the bacterial cells, bacterial cell components, cultured products, and processed products thereof of Pediococcus acidilactici. For example, preferably, the bacterial cells, bacterial cell components, cultured products, and processed products thereof contain nucleic acid, more preferably, the bacterial cells, bacterial cell components, cultured products, and processed products thereof contain RNA, and more preferably, the bacterial cells, bacterial cell components, cultured products, and processed products thereof contain double-stranded RNA.
[0097] The cells, cell components, cultures, and processed products of Pediococcus acidilactici can be used alone or in combination of two or more thereof. For example, RNA, preferably double-stranded RNA, can be isolated from the cells, cell components, cultures, and processed products of Pediococcus acidilactici and used. The method for isolating RNA from the cells, cell components, cultures, and processed products of Pediococcus acidilactici is not particularly limited. For example, as a method for isolating double-stranded RNA from the cells of Pediococcus acidilactici, the method described in Japanese Patent Gazette No. 5312322 can be cited.
[0098] The method for obtaining the bacterial cells, bacterial cell components, and cultured products of Pediococcus acidilactici containing double-stranded RNA, and processed products thereof is not particularly limited, and examples thereof include a method of obtaining the bacterial cells, bacterial cell components, and cultured products of Pediococcus acidilactici containing double-stranded RNA by inoculating Pediococcus acidilactici in a conventional MRS medium and culturing the cultured products at 35° C. to 45° C. for 24 to 72 hours, and the like.
[0099] As a specific example of a method for isolating double-stranded RNA from the cells, cell components, culture products of Pediococcus acidilactici, and their processed products, for example, the following method can be cited. That is, the cells, cell components, and culture products of Pediococcus acidilactici containing double-stranded RNA are subjected to heat sterilization treatment at 90°C to 100°C for 5 minutes to 20 minutes to obtain a heat sterilization treatment liquid. Then, the heat sterilization treatment liquid is subjected to solid-liquid separation means such as centrifugation to recover the solid component. Then, the solid component is washed and suspended in a buffer to obtain a suspension. Then, lysozyme is added to the suspension and heated at 35°C to 40°C to obtain a lysozyme treatment liquid. Then, SDS and proteinase K are added to the lysozyme treatment liquid and heated at 35°C to 40°C to obtain a protease treatment liquid. Then, the protease treatment liquid is subjected to phenol formaldehyde / chloroform / isoamyl alcohol treatment, and a crude nucleic acid extract is obtained as a supernatant by solid-liquid separation means such as centrifugation. The crude nucleic acid extract is a mixture of nucleic acids containing DNA, single-stranded RNA, double-stranded RNA, etc. Next, the crude nucleic acid extract is subjected to cellulose column chromatography to obtain purified double-stranded RNA. Cellulose column chromatography and subsequent high-level purification methods can be implemented according to the description of Japanese Patent Gazette No. 5312322.
[0100] Since Pediococcus acidilactici is generally ingested by humans for a long time and is highly safe, the composition of one embodiment of the present invention has high practicality and can be used in various applications as is or after processing.
[0101] The composition of one embodiment of the present invention is not particularly limited in its ingestion method, and can be applied to oral or parenteral administration. Examples of parenteral administration include injection and infusion by intradermal, subcutaneous, intravenous, intramuscular administration, percutaneous administration, and inhalation from the mucous membrane of the nose, pharynx, etc., but are not limited thereto.
[0102] The ingestion subject of the composition of one embodiment of the present invention is not particularly limited, and examples thereof include: animals, especially mammals, such as humans, dogs, cats, cattle, horses, pigs, sheep, etc., among which humans are particularly preferred. The ingestion subject may be a healthy subject, but is preferably a subject for which an anti-disease effect and / or an immune activation effect is desired.
[0103] The composition of one embodiment of the present invention may contain active ingredients and other ingredients in combination according to the application. That is, the composition of one embodiment of the present invention may contain various ingredients as other ingredients in addition to the bacterial cells, bacterial cell components, cultures, and processed products of Pediococcus acidilactici as long as the purpose of the present invention can be achieved.
[0104] As other ingredients, for example, animal and plant food materials such as sugar sweeteners, stabilizers, emulsifiers, starch, starch processed products, starch degradation products, salt, edible flavors, edible coloring, acidulant, flavor raw materials, nutrients, fruit juice, eggs, etc., and additives used in common food processing and / or pharmaceutical processing such as excipients, fillers, binders, thickeners, aromatic oils, preservatives, buffers, etc. The amount of other ingredients used is not particularly limited as long as it does not hinder the solution of the subject of the present invention, and can be appropriately set.
[0105] The composition of one embodiment of the present invention is not particularly limited as long as it is in a commonly used form, and can be in various forms such as solid, liquid, gel, suspension, cream, sheet, stick, powder, granular, granular, tablet, rod, plate, block, paste, capsule, and caplet.
[0106] The composition of one embodiment of the present invention, for example, in the case of an oral composition, can be made into an enteric composition as a substance that can deliver the bacterial cells, bacterial components, cultured products, and processed products of Pediococcus acidilactici to the small intestine via the esophagus and stomach. The enteric composition is not particularly limited as long as it is a composition in a form that is insoluble in gastric acid but soluble in the small intestine, and examples thereof include compositions in the form of acid-resistant microcapsules and liposomes.
[0107] The amount of the active ingredient is not particularly limited as long as it is an amount that can confirm the expression inhibitory effect on FcεRI of plasmacytoid dendritic cells, or the expression inhibitory effect on FcεRI of plasmacytoid dendritic cells and the production promoting effect on interferon-α of plasmacytoid dendritic cells. For oral compositions, it is, for example, 0.0001% to 99% by mass, preferably 0.001% to 90% by mass, relative to the entire composition; for parenteral compositions, it is, for example, 0.00001% to 99% by mass, preferably 0.0001% to 90% by mass.
[0108] The intake amount of the composition of one embodiment of the present invention is not particularly limited, and can be appropriately set according to the characteristics of the individual taking the intake, such as the age, physique, symptoms, etc. of the individual taking the intake; the intake method; the application site, etc. As the intake amount of the composition of one embodiment of the present invention, for example, the intake amount of the composition with the bacterial body of lactic acid bacteria as the active ingredient is 1 mg / body weight 60 kg / day to 1000 mg / body weight 60 kg / day. The number of intakes is not particularly limited, for example, once to three times a day, and the number of intakes can be appropriately increased or decreased according to the intake amount.
[0109] The composition of one embodiment of the present invention can be taken alone, or in the form of a food and beverage composition and a pharmaceutical composition with the composition. Therefore, a specific embodiment of the present invention is a food and beverage composition, a pharmaceutical composition, a cosmeceutical composition, a cosmetic composition, an animal feed composition, etc. containing an active ingredient or containing the composition of one embodiment of the present invention.
[0110] In the case where the composition of one embodiment of the present invention is a composition for food and drink, as long as it can at least play an effective role after ingestion, it can take the form of all food and drink. For example, beverages such as juice drinks, vegetable juices, fruit and vegetable juices, tea drinks, coffee drinks, sports drinks, refreshing drinks, health drinks, etc.; dairy products such as yogurt and cheese, etc.; processed food and drink such as soup, noodles, pudding, jam, etc.; desserts such as chewing gum, candy, sheet candy, soft candy, chocolate, biscuits, snacks, etc.; frozen desserts such as ice cream, shaved ice, popsicles, etc.; seasonings such as soy sauce and miso, etc.
[0111] A specific embodiment of the composition of food and drink is, for example, a food and drink having certain functionality to a living body, i.e., a functional food and drink. Functional food and drink, in addition to so-called healthy food and drink such as food and drink for specific health care, functional declaration food and drink, nutritional function food and drink, health function food and drink, food and drink for special use, nutritional supplement food and drink, health supplement food and drink, nutritional supplement, beauty food and drink, etc., also includes: food and drink for infants, food and drink for pregnant women and parturients, food and drink for elderly people, etc. Further, functional food and drink includes a healthy food and drink applicable to a health claim (Health claim) of a food standard based on a code (FAO / WHO Codex Alimentarius Commission).
[0112] The packaging form of the food and drink composition is not particularly limited and can be appropriately selected according to the applicable form, and examples thereof include packaging, bottles, cans, and pouches made of materials such as plastics such as coated paper, PET, and PTP, metals such as aluminum, and glass.
[0113] In the case where the composition of one embodiment of the present invention is a pharmaceutical composition, as long as it exerts an expression inhibitory effect on FcεRI of plasmacytoid dendritic cells, preferably an expression inhibitory effect on FcεRI of plasmacytoid dendritic cells and an effect of promoting the production of interferon-α of plasmacytoid dendritic cells after use, and exhibits the corresponding desired anti-disease effect, all forms of pharmaceuticals can be used.
[0114] The dosage form of the pharmaceutical composition is not particularly limited, and examples thereof include injections (muscular, subcutaneous, intradermal), oral preparations, nasal drops, etc. For example, the pharmaceutical composition can be prepared as a vaccine for exerting an antiviral effect. When the pharmaceutical composition is in the form of a vaccine, it can also be a mixed cocktail vaccine containing multiple active ingredients.
[0115] The method for producing the composition according to one embodiment of the present invention is not particularly limited, and examples thereof include a method of mixing Pediococcus acidilactici cells, cell components, cultures, and processed products thereof with any other components to form a desired dosage form.
[0116] As a specific embodiment of the method for producing a composition according to one embodiment of the present invention, for example, the following method can be cited. That is, by inoculating lactic acid Pediococcus in an MRS medium, culturing at the optimal temperature of lactic acid Pediococcus ± 5°C to 20°C for 12 hours to 72 hours, a culture is obtained. Then, the culture is subjected to heat sterilization treatment at 90°C to 100°C for 5 minutes to 20 minutes to obtain a heat sterilization treatment liquid. Then, the heat sterilization treatment liquid is subjected to generally known solid-liquid separation means such as ultrafiltration membrane and centrifugal concentrator to remove the culture medium and recover the bacterial body. Then, the obtained bacterial body is washed with a washing liquid such as water and saline to obtain the bacterial body of lactic acid Pediococcus. The bacterial body obtained in this way, the bacterial body suspension in which the bacterial body is suspended in a washing liquid such as water and saline, the dry powder obtained by drying the bacterial body, etc., can be used as an active ingredient of the composition according to one embodiment of the present invention. The method of drying treatment is not particularly limited, and examples thereof include natural drying, air drying, spray drying, freeze drying, etc.
[0117] The method for producing a composition according to one embodiment of the present invention can include various steps and / or operations before or after the above steps, or during the steps, as long as the object of the present invention can be achieved.
[0118] Another embodiment of the present invention is a method for screening lactic acid bacteria for activating plasmacytoid dendritic cells that can be used as an active ingredient of the composition of one embodiment of the present invention. The screening method of one embodiment of the present invention can be roughly divided into two specific embodiments.
[0119] The screening method according to a first specific embodiment of the present invention is a method using the inhibitory effect on the expression of FcεRI of plasmacytoid dendritic cells as an indicator, and comprises at least the following steps:
[0120] The steps of culturing a test solution containing at least one component selected from the group consisting of bacterial cells, bacterial components, and culture products of lactic acid bacteria and processed products thereof, and plasmacytoid dendritic cells, and culturing a control solution containing no such component and containing plasmacytoid dendritic cells;
[0121] A step of measuring the expression level of FcεRI in the plasmacytoid dendritic cells in the test solution and the control solution after culture; and
[0122] A step of determining that the component has an effective component for activating plasmacytoid dendritic cells when the measured expression level of FcεRI by plasmacytoid dendritic cells in the test solution is lower than the expression level of FcεRI by plasmacytoid dendritic cells in the control solution.
[0123] The screening method of the second specific embodiment of the present invention is a method using the inhibitory effect on the expression of FcεRI of plasmacytoid dendritic cells and the promoting effect on the production of interferon-α by plasmacytoid dendritic cells as indicators, and comprises at least the following steps:
[0124] The steps of culturing a test solution containing at least one component selected from the group consisting of bacterial cells, bacterial components, and culture products of lactic acid bacteria and processed products thereof, and plasmacytoid dendritic cells, and culturing a control solution containing no such component and containing plasmacytoid dendritic cells;
[0125] A step of measuring the amount of interferon-α produced by the plasmacytoid dendritic cells and the amount of FcεRI expressed by the plasmacytoid dendritic cells in the test solution and the control solution after the culture; and
[0126] A process for determining that the component is an effective component for activating plasmacytoid dendritic cells when the amount of interferon-α produced in the test solution is greater than the amount of interferon-α produced in the control solution and the amount of FcεRI expressed in the test solution is less than the amount of FcεRI expressed in the control solution.
[0127] In the screening method according to one embodiment of the present invention, the co-culture of the test substance and plasmacytoid dendritic cells, the measurement of the expression level of FcεRI in plasmacytoid dendritic cells, and the production level of interferon-α in plasmacytoid dendritic cells can be carried out with reference to the above description.
[0128] The screening method according to one embodiment of the present invention can include various steps and / or operations before or after the above steps, or during the steps, as long as the purpose of the present invention can be achieved.
[0129] The present invention will be described in further detail below by way of examples, but the present invention is not limited to these examples, and the present invention can be implemented in various forms as long as the subject of the present invention can be solved.
[0130] Example
[0131] [Example 1. Test for inhibiting the expression of FcεRI of lactic acid bacteria]
[0132] The inhibitory effect on the expression of high-affinity IgE receptor (FcεRI) possessed by lactic acid bacteria was evaluated as follows.
[0133] 1-1. Preparation of lactic acid bacteria suspension
[0134] As lactic acid bacteria, Pediococcus acidilactici ( Pediococcus acidilactici ) K15, K226, K531 and JCM8797; Pediococcus pentosaceus ( P. pentosaceus )NRIC99 strain; Lactobacillus johnsonii ( Lactobacillus johnsonii )JCM1022 strain (K1167 strain); Lactobacillus delbrueckii ( L. delbrueckii )NRIC1688 strain (K1175 strain); Lactobacillus pentosus ( L. pentosus )K133 strain and NRIC1836 strain.
[0135] The strains of "NRIC" are obtained from Tokyo University of Agriculture, and the strains of "JCM" are obtained from RIKEN. In addition, as lactic acid bacteria-containing substances, strains K15, K226, K531, and K133 were isolated from rice bran, pickles, wine grapes, and rice bran.
[0136] Each lactic acid strain was 1×10 7 The lactic acid bacteria stock solution was prepared by inoculating the lactic acid bacteria stock solution at 26°C to 30°C for 24 to 36 hours, and then boiling and sterilizing the lactic acid bacteria stock solution at 95°C for 10 minutes. The bacterial cells obtained by centrifuging the culture sterilization solution were washed with physiological saline and then suspended in physiological saline to prepare a lactic acid bacteria suspension.
[0137] 1-2. Isolation of plasmacytoid dendritic cells (pDC)
[0138] Peripheral blood mononuclear cells were isolated from 50 ml of peripheral blood of eight subjects A to H from non-viral healthy subjects using lymphocyte separation solution (Nacalai Tesque) by low-density gradient centrifugation. CD14-positive cells were then removed from peripheral blood mononuclear cells using CD14 magnetic beads (Miltenyi Biotec) and MACS (Miltenyi Biotec). After removing CD14-positive cells, FITC-labeled CD304 antibody (Miltenyi Biotec) was used to label the cells, which were then reacted with FITC magnetic beads (Miltenyi Biotec), and CD304-positive cells were isolated by MACS, and the cells (CD14-negative CD304-positive) were used as pDC.
[0139] 1-3. Co-culture of lactic acid bacteria and pDC
[0140] IMDM medium (GIBCO) containing 10% FBS (Hyclone), 25 mM D-glucose, 25 mM HEPES, and 1 μM sodium pyruvate was used as the cell culture medium. 1×10 7 of each lactic acid strain and 2×10 4 or 4×10 4 pDCs were cultured 24 hours later, and the cells and supernatant were collected. The supernatant collected from the wells where pDCs were cultured without lactic acid bacteria was used as a control. Table 1 shows the subjects from which the pDCs used were derived and the combinations of lactic acid bacteria used.
[0141] [Table 1]
[0142] Serial number Lactic acid strain Subject 1 L. johnsonii K1167 C, D, E, F, G 2 L. delbrueckii K1175 B, D, F, G 3 L. pentosus NRlC1836 F, G 4 L. pentosus K133 F, G 5 P. pentosaceus NR / C99 B, D, F, G, H 6 P. acidilactici K226 F, G 7 P. acidilactici K531 F, G 8 P. acidilactici JCM8797 A, B, C, D, E, F, G, H 9 P. acidilactici K15 A, B, C, D, H
[0143] 1-4. Determination of FcεRI expression inhibitory activity
[0144] Using cells recovered after co-culture, the expression of FcεRIα was quantified using 7AAD (BD Pharmingen) and PE-labeled anti-FcεRIα (Bio Regend) antibodies using flow cytometry (FACS Aria II, Becton Dickinson). The obtained quantitative values were set as 1 for the control value, and the values when each lactic acid strain was used were obtained by relative value.
[0145] 1-5. Evaluation
[0146] Among the lactic acid strains tested, Lactobacillus johnsonii K1167, Lactobacillus delbrueckii K1175, and Lactobacillus pentosus NRIC1836 showed values higher than the control (>1) in pDCs derived from more than one subject. In particular, Lactobacillus johnsonii K1167 and Lactobacillus delbrueckii K1175 showed values higher than the control in pDCs derived from two subjects. These lactic acid strains were judged not to have an FcεRI expression inhibitory effect.
[0147] For the rest of the lactic acid strains, Figure 1 The results of calculating the average value among subjects for each lactic acid strain based on the FcεRI expression level (relative value) of pDC selected from each subject are shown. Figure 1 As shown, the expression levels of FcεRI in pDC of Lactobacillus pentosus, Pediococcus acidilactici and Pediococcus pentosaceus were as low as 0.9 or less. In particular, the expression level of FcεRI in pDC of Pediococcus acidilactici was low in all strains.
[0148] From the above results, it was confirmed that lactic acid bacteria of the genus Pediococcus have an inhibitory effect on the expression of FcεRI of pDC, and that Pediococcus acidilactici has a particularly excellent inhibitory effect on the expression of FcεRI of pDC.
[0149] [Example 2. Test for promoting interferon-α production by lactic acid bacteria]
[0150] The interferon-α (IFN-α) production promoting effect of lactic acid bacteria was evaluated as follows.
[0151] 2-1. Measurement of IFN-α production-promoting activity
[0152] The concentration of IFN-α was quantified using a human IFN-α paired antibody pair (eBioscience) using the culture supernatant recovered after co-culture of lactic acid bacteria and pDC in Example 1. The obtained quantitative values were determined relative to the values of the control as 1, and the values when each lactic acid strain was used.
[0153] 2-2. Evaluation
[0154] Among the lactic acid strains tested, for lactic acid strains other than Lactobacillus johnsonii K1167, it was confirmed that the pDC had an induction ability to produce IFN-α regardless of the subject from which the pDC was derived and the lactic acid strain. For Lactobacillus johnsonii K1167, the amount of IFN-α produced was very low (average of 1.8 between subjects), and only a slight increase was seen relative to the control.
[0155] On the other hand, the strain with the highest ability to induce IFN-α production in pDC among the lactic acid strains tested was Lactobacillus delbrueckii K1175. When combined with the results of Example 1 showing that Lactobacillus delbrueckii K1175 did not have an inhibitory effect on FcεRI expression, it can be seen that the effect of promoting IFN-α production in pDC and the effect of inhibiting FcεRI expression are not necessarily correlated.
[0156] The above results show that the present inventors have discovered for the first time that lactic acid bacteria of the genus Pediococcus such as Pediococcus acidilactici and Pediococcus pentosaceus have an effect of inhibiting the expression of FcεRI by pDC and, further, have an effect of promoting the production of IFN-α, which is a very surprising phenomenon.
[0157] [Example 3. Comparative study with TLR ligands related to the inhibitory effect on FcεRI expression]
[0158] Comparison of the FcεRI expression inhibitory activity of Pediococcus acidilactici K15 strain and the activity of TLR ligands was evaluated as follows.
[0159] 3-1. Determination of the FcεRI expression inhibitory effect of TLR ligands
[0160] For pDCs selected from subject H, co-culture with pDCs was performed in the same manner as in Example 1, except that TLR7 ligand imiquimod (R837; invivogen), TLR8 ligand ssRNA40 / LyoVec (invivogen), and TLR9 ligand ODN2216 (CpG; invivogen) were used instead of each lactic acid strain at a final concentration of 10 μg / ml. The supernatant recovered from the wells where only pDCs were cultured without using the K15 strain or the ligand was used as a control.
[0161] Using the cells recovered after co-culture, RNA was extracted by NucleoSpin RNA XS (MACHEREY-NAGEL), and the mRNA expression levels of FcεRIα and β-actin were measured by quantitative PCR using PrimeScript RT Reagent Kit (Takara Biotech) and TB Green Premix Ex Taq II (Takara Biotech). Each primer was purchased from Takara Biotech. The mRNA expression level of FcεRIα was standardized using the measured value of β-actin, and the value of the control (Med) was taken as 1, and the value when the K15 strain or ligand was used was obtained by relative value.
[0162] 3-2. Evaluation
[0163] Figure 2The relative amounts of FcεRI mRNA of K15 strain and each TLR ligand are shown. Figure 2 As shown, based on the relative amount of FcεRI mRNA, it was found that the FcεRI expression inhibitory activity of the K15 strain was comparable to or stronger than the activity of each TLR ligand.
[0164] Industrial Applicability
[0165] A composition according to one embodiment of the present invention comprises an active ingredient that can be used in either an oral or parenteral manner, and is useful for individuals who ingest the composition and expect antiviral activity, anti-infective activity, anti-allergic activity, anti-hay fever activity, and anti-asthma activity by inhibiting the expression of FcεRI on plasmacytoid dendritic cells, and can be used as a food, medicine, cosmeceuticals, cosmetics, etc. that contribute to the health and welfare of such individuals who ingest the composition.
[0166] CROSS-REFERENCE TO RELATED APPLICATIONS
[0167] This application claims the benefit of priority based on Japanese Patent Application No. 2018-150152, filed on August 9, 2018, the contents of which are incorporated herein by reference.
Claims
1. Use of a composition for inhibiting the expression of FcεRI of plasmacytoid dendritic cells in vitro, the composition comprising a member selected from Pediococcus acidilactici ( Pediococcus acidilactici ) bacterial cell, wherein the Pediococcus acidilactici is selected from the group consisting of Pediococcus acidilactici K15 strain, K226 strain, K531 strain and JCM8797 strain.
2. The use according to claim 1, wherein the composition has an effect of promoting the production of interferon-α by plasmacytoid dendritic cells.
3. The use according to any one of claims 1 to 2, wherein the composition has an equal amount of Lactobacillus pentosus ( Lactobacillus pentosus ) strain, and had a higher inhibitory effect on the expression of FcεRI in plasmacytoid dendritic cells than that in K133 strain.
